A 3-Year, State of the Art, Observational Study of Fingolimod in Patients with Multiple Sclerosis for Patient Management in Daily Clinical Practice (PANGAEA 2.0)
Latest Information Update: 17 Jun 2023
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PANGAEA 2.0; PANGAEA-2
- Sponsors Novartis
- 27 Apr 2023 Status changed to completed, according to Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 27 Apr 2023 Final results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 12 Oct 2018 Interim results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis